BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 27502921)

  • 1. Postoperative chemoradiotherapy versus chemotherapy for R0 resected gastric cancer with D2 lymph node dissection: an up-to-date meta-analysis.
    Zhou ML; Kang M; Li GC; Guo XM; Zhang Z
    World J Surg Oncol; 2016 Aug; 14(1):209. PubMed ID: 27502921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative chemoradiotherapy versus postoperative chemotherapy for completely resected gastric cancer with D2 Lymphadenectomy: a meta-analysis.
    Huang YY; Yang Q; Zhou SW; Wei Y; Chen YX; Xie DR; Zhang B
    PLoS One; 2013; 8(7):e68939. PubMed ID: 23874819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.
    Park SH; Sohn TS; Lee J; Lim DH; Hong ME; Kim KM; Sohn I; Jung SH; Choi MG; Lee JH; Bae JM; Kim S; Kim ST; Park JO; Park YS; Lim HY; Kang WK
    J Clin Oncol; 2015 Oct; 33(28):3130-6. PubMed ID: 25559811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
    Dikken JL; Jansen EP; Cats A; Bakker B; Hartgrink HH; Kranenbarg EM; Boot H; Putter H; Peeters KC; van de Velde CJ; Verheij M
    J Clin Oncol; 2010 May; 28(14):2430-6. PubMed ID: 20368551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphadenectomy extent and survival of patients with gastric carcinoma: a systematic review and meta-analysis of time-to-event data from randomized trials.
    Mocellin S; Nitti D
    Cancer Treat Rev; 2015 May; 41(5):448-54. PubMed ID: 25814393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is postoperative adjuvant chemoradiotherapy efficacious and safe for gastric cancer patients with D2 lymphadenectomy? A meta-analysis of the literature.
    Liang JW; Zheng ZC; Yu T; Wang X; Zhang JJ
    Eur J Surg Oncol; 2014 Dec; 40(12):1614-21. PubMed ID: 24813809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extent of lymph node dissection for adenocarcinoma of the stomach.
    Mocellin S; McCulloch P; Kazi H; Gama-Rodrigues JJ; Yuan Y; Nitti D
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD001964. PubMed ID: 26267122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. D2-resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy.
    Peng J; Wei Y; Zhou F; Dai J; Zhong Y; Xie C; Qin Y; Gong J; Xiong B; Zhou Y
    Cancer Med; 2016 Oct; 5(10):2773-2780. PubMed ID: 27666138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemoradiation versus chemotherapy for stage III gastric cancer after surgery with curative intent.
    Turanli S; Atalay C; Berberoglu U; Gulben K
    J Cancer Res Ther; 2015; 11(2):369-74. PubMed ID: 26148602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis.
    Datta J; McMillan MT; Ecker BL; Karakousis GC; Mamtani R; Plastaras JP; Giantonio BJ; Drebin JA; Dempsey DT; Fraker DL; Roses RE
    Ann Surg; 2016 Feb; 263(2):298-305. PubMed ID: 26135687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
    Lee SJ; Sohn TS; Lee J; Park SH; Park JO; Lim DH; Park YS; Lim HY; Choi MG; Lee JH; Bae JM; Kim S; Kang WK
    Anticancer Res; 2014 Nov; 34(11):6585-91. PubMed ID: 25368262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of patients with lymph node metastasis from gastric cancer who may benefit from adjuvant chemoradiotherapy after D2 dissection--do N3 patients benefit from additional radiation?
    Fan M; Li G; Shen L; Zhang H; Liang L; Zhang Z
    Br J Radiol; 2016; 89(1059):20150758. PubMed ID: 26728420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection.
    Wang X; Shen Y; Zhu H; Zhao Y; Li Z; Qiu M; Li Q; Gou H; Yang Y; Cao D; Liu J; Yi C; Liao Z; Luo D; Bi F; Xu F
    Gastric Cancer; 2016 Jan; 19(1):245-54. PubMed ID: 25609451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of adjuvant chemoradiotherapy on overall survival of gastric cancer patients submitted to D2 lymphadenectomy.
    Jácome AA; Wohnrath DR; Scapulatempo Neto C; Fregnani JH; Quinto AL; Oliveira AT; Vazquez VL; Fava G; Martinez EZ; Santos JS
    Gastric Cancer; 2013 Apr; 16(2):233-8. PubMed ID: 22740060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resection for gastric cancer in the community.
    van de Velde CJ
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S90-3. PubMed ID: 16399441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival outcomes and patterns of failure after D2 dissection and adjuvant chemoradiotherapy for locally advanced gastric cancer: a retrospective study.
    Yang W; Hu R; Li GC; Zhou ML; Wang Y; Shen LJ; Liang LP; Zhang Z
    Br J Radiol; 2018 Sep; 91(1089):20170594. PubMed ID: 29927628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer.
    Kim MS; Lim JS; Hyung WJ; Lee YC; Rha SY; Keum KC; Koom WS
    World J Gastroenterol; 2015 Mar; 21(9):2711-8. PubMed ID: 25759540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake?
    Reddavid R; Sofia S; Chiaro P; Colli F; Trapani R; Esposito L; Solej M; Degiuli M
    World J Gastroenterol; 2018 Jan; 24(2):274-289. PubMed ID: 29375213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative adjuvant treatment for gastric cancer improves long-term survival after curative resection and D2 lymphadenectomy. Results from a Latin American Center.
    Norero E; Bustos M; Herrera ME; Cerda J; González P; Ceroni M; Martínez C; Briceño E; Rojas H; Cártes R; Lopez V; Hidalgo V; Báez S; Caracci M; Viñuela E; Díaz A
    Eur J Surg Oncol; 2016 Jan; 42(1):94-102. PubMed ID: 26577767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The prognostic influence of D2 lymphadenectomy with para-aortic lymph nodal dissection for gastric cancer in N3 stage].
    Liang YX; Liang H; Ding XW; Wang XN; Zhang L; Wu LL; Liu HG; Jiao XG
    Zhonghua Wai Ke Za Zhi; 2013 Dec; 51(12):1071-6. PubMed ID: 24499714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.